Senseonics (NYSE:SENS) Reaches New 52-Week High – Here’s What Happened

Senseonics Holdings, Inc. (NYSE:SENS)’s share price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $0.95 and last traded at $0.99, with a volume of 3044314 shares trading hands. The stock had previously closed at $0.91.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on SENS shares. HC Wainwright reaffirmed a “buy” rating and set a $2.00 target price on shares of Senseonics in a research note on Friday, November 15th. StockNews.com initiated coverage on shares of Senseonics in a research note on Thursday, December 26th. They set a “sell” rating on the stock.

Senseonics Stock Performance

The stock’s 50-day simple moving average is $0.44 and its 200 day simple moving average is $0.40. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The company has a market capitalization of $598.30 million, a PE ratio of -7.73 and a beta of 0.64.

Senseonics (NYSE:SENS) last issued its earnings results on Thursday, November 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. The company had revenue of $4.26 million during the quarter, compared to analyst estimates of $4.02 million. As a group, research analysts expect that Senseonics Holdings, Inc. will post -0.14 earnings per share for the current fiscal year.

Insider Activity

In other Senseonics news, CEO Timothy T. Goodnow purchased 315,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was purchased at an average price of $0.31 per share, for a total transaction of $97,650.00. Following the purchase, the chief executive officer now directly owns 11,310,355 shares in the company, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Frederick T. Sullivan purchased 124,933 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $0.38 per share, with a total value of $47,474.54. Following the purchase, the chief financial officer now owns 2,478,844 shares in the company, valued at $941,960.72. This trade represents a 5.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Senseonics

A number of large investors have recently bought and sold shares of the company. FMR LLC increased its holdings in shares of Senseonics by 48,267.2% in the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after purchasing an additional 167,970 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Senseonics during the 3rd quarter valued at about $117,000. Symmetry Partners LLC purchased a new position in Senseonics during the 3rd quarter valued at about $164,000. Cubist Systematic Strategies LLC increased its holdings in Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after acquiring an additional 85,501 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after acquiring an additional 179,103 shares in the last quarter. Hedge funds and other institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.